About InterMune
InterMune is a company based in Brisbane (United States) founded in 1998 was acquired by Legacy Pharma in February 2025.. The company has 359 employees as of December 31, 2014. InterMune operates in a competitive market with competitors including Zai Lab, aTyr Pharma, ReCode Therapeutics, GEn1E and Pulmatrix, among others.
- Headquarter Brisbane, United States
- Employees 359 as on 31 Dec, 2014
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
Roche
& 1 more
-
Employee Count
359
as on Dec 31, 2014
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of InterMune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in InterMune
InterMune has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Roche and Legacy Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
Founded Year | Domain | Location | |
|
Legacy Pharma is engaged in distributing prescription pharmaceutical products.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by InterMune
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - InterMune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Intermune Comparisons
Competitors of InterMune
InterMune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zai Lab, aTyr Pharma, ReCode Therapeutics, GEn1E and Pulmatrix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Protein biologics are developed for treating rare diseases.
|
|
| domain | founded_year | HQ Location |
Precision medicines for lung-related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of respiratory diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about InterMune
When was InterMune founded?
InterMune was founded in 1998.
Where is InterMune located?
InterMune is headquartered in Brisbane, United States. It is registered at Brisbane, California, United States.
How many employees does InterMune have?
As of Dec 31, 2014, the latest employee count at InterMune is 359.
What does InterMune do?
InterMune was founded in 1998 and is headquartered in Brisbane, United States. Operations in the biotechnology sector center on research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases. Idiopathic pulmonary fibrosis is addressed through Pirfenidone, approved in the EU as Esbriet and under Phase 3 trials for U.S. registration. Small-molecule therapeutics and biomarkers are pursued for monitoring serious pulmonary conditions.
Who are the top competitors of InterMune?
InterMune's top competitors include Zai Lab, aTyr Pharma and ReCode Therapeutics.
Who are InterMune's investors?
InterMune has 2 investors. Key investors include Roche, and Legacy Pharma.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.